Capmatinib Hydrochloride
Brand name: Tabrecta
Rank #475 of 500 drugs by total cost
$15.1M
Total Cost
824
Total Claims
$15.1M
Total Cost
58
Prescribers
$18K
Cost per Claim
0
Beneficiaries
832
30-Day Fills
$261K
Avg Cost/Provider
14
Avg Claims/Provider
About Capmatinib Hydrochloride
Capmatinib Hydrochloride (sold as Tabrecta) was prescribed 824 times by 58 Medicare Part D providers in 2023, costing the program $15.1M. At $18K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 472 | Primidone (Primidone) | $15.3M | 450,535 |
| 473 | Fluocinonide (Fluocinonide) | $15.3M | 217,528 |
| 474 | Diclofenac Potassium (Diclofenac Potassium) | $15.2M | 96,736 |
| 475 | Capmatinib Hydrochloride (Tabrecta) | $15.1M | 824 |
| 476 | Berotralstat Hydrochloride (Orladeyo) | $15.1M | 374 |
| 477 | Lansoprazole (Lansoprazole) | $15.0M | 309,355 |
| 478 | Raloxifene Hcl (Raloxifene Hcl) | $14.8M | 198,063 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology